196 related articles for article (PubMed ID: 15169799)
1. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
Pollack A; DeSilvio M; Khor LY; Li R; Al-Saleem TI; Hammond ME; Venkatesan V; Lawton CA; Roach M; Shipley WU; Hanks GE; Sandler HM
J Clin Oncol; 2004 Jun; 22(11):2133-40. PubMed ID: 15169799
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10.
Li R; Heydon K; Hammond ME; Grignon DJ; Roach M; Wolkov HB; Sandler HM; Shipley WU; Pollack A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4118-24. PubMed ID: 15217948
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08.
Verhoven B; Yan Y; Ritter M; Khor LY; Hammond E; Jones C; Amin M; Bahary JP; Zeitzer K; Pollack A
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):317-23. PubMed ID: 23474109
[TBL] [Abstract][Full Text] [Related]
4. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer.
Abramowitz MC; Li T; Buyyounouski MK; Ross E; Uzzo RG; Pollack A; Horwitz EM
Cancer; 2008 Jan; 112(1):55-60. PubMed ID: 17968996
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.
Cowen D; Troncoso P; Khoo VS; Zagars GK; von Eschenbach AC; Meistrich ML; Pollack A
Clin Cancer Res; 2002 May; 8(5):1148-54. PubMed ID: 12006531
[TBL] [Abstract][Full Text] [Related]
6. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
Buyyounouski MK; Hanlon AL; Horwitz EM; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1291-8. PubMed ID: 15817330
[TBL] [Abstract][Full Text] [Related]
7. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.
Jacob R; Hanlon AL; Horwitz EM; Movsas B; Uzzo RG; Pollack A
Cancer; 2004 Feb; 100(3):538-43. PubMed ID: 14745870
[TBL] [Abstract][Full Text] [Related]
8. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
9. Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10.
Torres-Roca JF; DeSilvio M; Mora LB; Khor LY; Hammond E; Ahmad N; Jove R; Forman J; Lee RJ; Sandler H; Pollack A
Urology; 2007 Mar; 69(3):505-9. PubMed ID: 17382154
[TBL] [Abstract][Full Text] [Related]
10. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
[TBL] [Abstract][Full Text] [Related]
11. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
Roach M; DeSilvio M; Lawton C; Uhl V; Machtay M; Seider MJ; Rotman M; Jones C; Asbell SO; Valicenti RK; Han S; Thomas CR; Shipley WS;
J Clin Oncol; 2003 May; 21(10):1904-11. PubMed ID: 12743142
[TBL] [Abstract][Full Text] [Related]
13. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
15. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
16. Analysis of competing risk parameters in irradiated prostate cancer patients.
Mayer R; Pummer K; Quehenberger F; Mayer E; Feigl G; Langsenlehner U; Hackl A
Strahlenther Onkol; 2003 Jul; 179(7):452-7. PubMed ID: 12835881
[TBL] [Abstract][Full Text] [Related]
17. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
[TBL] [Abstract][Full Text] [Related]
18. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
20. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.
D'Ambrosio DJ; Hanlon AL; Al-Saleem T; Feigenberg SJ; Horwitz EM; Uzzo RG; Pollack A; Buyyounouski MK
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1082-7. PubMed ID: 17241749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
